Iris Behrmann

This paper identifies FX-11 as a mitochondrial uncoupler that inhibits melanoma cell growth, including drug-resistant sublines, by altering energy metabolism rather than targeting lactate dehydrogenase.

This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.

The paper identifies FK866, a NAMPT inhibitor, as effective against drug-naive and -resistant melanoma cells in various culture conditions without affecting healthy cells.

This study investigates melanoma cell susceptibility to ferroptosis and drug resistance using novel 3D culture models and medium compositions.